Treatment of Latent Tuberculosis Infection-An Update

Treatment of latent tuberculosis infection (LTBI) is an important component of TB control and elimination. LTBI treatment regimens include once-weekly isoniazid plus rifapentine for 3 months, daily rifampin for 4 months, daily isoniazid plus rifampin for 3-4 months, and daily isoniazid for 6-9 month...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinics in chest medicine Ročník 40; číslo 4; s. 839
Hlavní autoři: Huaman, Moises A, Sterling, Timothy R
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.12.2019
Témata:
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Female
Humans
Latent Tuberculosis - drug therapy
Male
Prevention and control
Treatment
Tuberculosis
Review
Latent tuberculosis infection
Isoniazid
Rifampin
Rifapentine
ISSN:1557-8216, 1557-8216
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Treatment of latent tuberculosis infection (LTBI) is an important component of TB control and elimination. LTBI treatment regimens include once-weekly isoniazid plus rifapentine for 3 months, daily rifampin for 4 months, daily isoniazid plus rifampin for 3-4 months, and daily isoniazid for 6-9 months. Isoniazid monotherapy is efficacious in preventing TB disease, but the rifampin- and rifapentine-containing regimens are shorter and have similar efficacy, adequate safety, and higher treatment completion rates. Novel vaccine strategies, host immunity-directed therapies and ultrashort antimicrobial regimens for TB prevention, such as daily isoniazid plus rifapentine for 1 month, are under evaluation.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1557-8216
1557-8216
DOI:10.1016/j.ccm.2019.07.008